Gilead shares fall as remdesivir's efficacy to treat COVID-19 in question
Gilead shares fell about 4%.
Vials of investigational coronavirus disease (COVID-19) treatment drug are capped at a facility.(photo credit: GILEAD SCIENCES INC/HANDOUT VIA REUTERS)